β cell differentiation  (Proteintech)

Journal: Stem Cells Translational Medicine

Article Title: Toward Precision Medicine with Human Pluripotent Stem Cells for Diabetes

doi: 10.1093/stcltm/szac030

Figure Lengend Snippet: Using patient-derived hPSCs for β-cell replacement therapy and personalized treatment for patients with diabetes. Induced pluripotent stem cells (iPSCs) can be generated from patients with different forms of diabetes. Induced pluripotent stem cells generated from patients with monogenic diabetes (MD) due to specific mutations can be corrected to generate healthy iPSCs. Corrected MD-iPSCs and those generated from patients with type 2 diabetes (T2D) can be differentiated into pancreatic progenitors and then insulin-secreting β cells. The differentiated cells can be used for autologous cell therapy where the cells are transplanted back into T2D and MD patients without the need for immunosuppression. However, Patients with T1D would still require immunosuppression, or the pancreatic cells can be transplanted in a capsule to avoid using immunosuppressants.

Article Snippet: Furthermore, Vertex pharmaceuticals, running a Phase I/II clinical trial that transplants fully differentiated hPSC-derived β cells, infused into the hepatic portal vein of hypoglycemic patients with T1D, presented first set of results where they showed a 91% decrease in exogenous insulin administration for their first patient within 90 days, thus providing a huge breakthrough in the field of β-cell replacement therapy (NCT04786262).

Techniques: Derivative Assay, Generated

Journal: Stem Cells Translational Medicine

Article Title: Toward Precision Medicine with Human Pluripotent Stem Cells for Diabetes

doi: 10.1093/stcltm/szac030

Figure Lengend Snippet: Ongoing clinical trials using pancreatic cells derived from hPSCs to treat patients with diabetes.

Article Snippet: Furthermore, Vertex pharmaceuticals, running a Phase I/II clinical trial that transplants fully differentiated hPSC-derived β cells, infused into the hepatic portal vein of hypoglycemic patients with T1D, presented first set of results where they showed a 91% decrease in exogenous insulin administration for their first patient within 90 days, thus providing a huge breakthrough in the field of β-cell replacement therapy (NCT04786262).

Techniques: Derivative Assay

Journal: Stem Cells Translational Medicine

Article Title: Toward Precision Medicine with Human Pluripotent Stem Cells for Diabetes

doi: 10.1093/stcltm/szac030

Figure Lengend Snippet: Advances and limitations in generating pancreatic β cells from hPSCs. Multiple modifications in β-cell differentiation protocols are listed, along with limitations in obtaining hPSC-derived β cells representing adult human β cells persist. Use of ROCKII and YAP inhibition, as well as cytoskeletal depolymerizer during endocrine commitment improves proportion and functionality of the generated β cells. Furthermore, physical manipulation such as disassociation and reaggregation of the hPSC-derived endocrine clusters also improves maturity of β cells and eliminates non-β cells, such as α cells, delta cells or non-committed progenitors and polyhormonal cells, that are normally present in differentiated endocrine clusters along with β cells. However, key maturation markers are still absent from the differentiated β cells along with aberrant calcium signaling and dysfunctional mitochondria.

Article Snippet: Furthermore, Vertex pharmaceuticals, running a Phase I/II clinical trial that transplants fully differentiated hPSC-derived β cells, infused into the hepatic portal vein of hypoglycemic patients with T1D, presented first set of results where they showed a 91% decrease in exogenous insulin administration for their first patient within 90 days, thus providing a huge breakthrough in the field of β-cell replacement therapy (NCT04786262).

Techniques: Cell Differentiation, Derivative Assay, Inhibition, Generated